




Searching News Database: TLR9
HSMN NewsFeed - 24 Aug 2021
InDex Pharmaceuticals receives FDA clearance to start the phase III study CONCLUDE with cobitolimod
InDex Pharmaceuticals receives FDA clearance to start the phase III study CONCLUDE with cobitolimod
HSMN NewsFeed - 17 Apr 2008
Dynavax and Merck & Co., Inc. Update Status of Clinical Hold of Investigational Vaccine HEPLISAV(TM)
Dynavax and Merck & Co., Inc. Update Status of Clinical Hold of Investigational Vaccine HEPLISAV(TM)
HSMN NewsFeed - 17 Mar 2008
Dynavax and Merck & Co., Inc. Report Clinical Hold of Investigational Vaccine HEPLISAV
Dynavax and Merck & Co., Inc. Report Clinical Hold of Investigational Vaccine HEPLISAV
HSMN NewsFeed - 19 Sep 2007
Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
HSMN NewsFeed - 28 Jun 2007
Coley Pharmaceutical Group Grants Dynavax License for Commercialization of HEPLISAV(TM)
Coley Pharmaceutical Group Grants Dynavax License for Commercialization of HEPLISAV(TM)
HSMN NewsFeed - 21 May 2007
Idera Pharmaceuticals Announces Chief Financial Officer to Leave Company Effective July 31, 2007
Idera Pharmaceuticals Announces Chief Financial Officer to Leave Company Effective July 31, 2007
HSMN NewsFeed - 12 Apr 2007
Coley Pharmaceutical Group Licenses VaxImmune(TM) to Merck for Use in Vaccine Programs
Coley Pharmaceutical Group Licenses VaxImmune(TM) to Merck for Use in Vaccine Programs
HSMN NewsFeed - 23 Feb 2007
Dynavax Reports Interim, One-Year Data From Ragweed Allergy Trial at AAAAI
Dynavax Reports Interim, One-Year Data From Ragweed Allergy Trial at AAAAI
HSMN NewsFeed - 21 Feb 2007
Idera Pharmaceuticals Appoints Dr. Alice Bexon, Vice President of Clinical Development
Idera Pharmaceuticals Appoints Dr. Alice Bexon, Vice President of Clinical Development
HSMN NewsFeed - 20 Dec 2006
Dynavax Initiates Pivotal Phase 3 Trial for HEPLISAV(TM), Hepatitis B Vaccine
Dynavax Initiates Pivotal Phase 3 Trial for HEPLISAV(TM), Hepatitis B Vaccine
HSMN NewsFeed - 28 Nov 2006
Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Shows Statistically Significant Results in Phase 3 Trial
Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Shows Statistically Significant Results in Phase 3 Trial
HSMN NewsFeed - 4 Oct 2006
NEW ENGLAND JOURNAL OF MEDICINE Reports Positive Results From Dynavax' Ragweed Allergy Therapy Trial
NEW ENGLAND JOURNAL OF MEDICINE Reports Positive Results From Dynavax' Ragweed Allergy Therapy Trial
Additional items found! 13

Members Archive contains
13 additional stories matching:
TLR9
(Password required)
TLR9
(Password required)